Olema Pharmaceuticals (OLMA)
(Delayed Data from NSDQ)
$10.67 USD
+0.60 (5.96%)
Updated May 3, 2024 04:00 PM ET
After-Market: $10.66 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Olema Pharmaceuticals, Inc. [OLMA]
Reports for Purchase
Showing records 1 - 20 ( 22 total )
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Recap: Updated Ribo Combo Data to be Presented at ESMO Breast in May
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Palazestrant Combo Data Consistent With Previous Data; No Meaningful Exposure Impacts is a Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Recap: New Combo Data to be Presented at SABCS in Dec; Pivotal Study Enrollment Initiation on Track for 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Palazestrant Phase 2 Monotherapy Is a Home Run, in Our View; Increases Our Confidence in Phase 3 Success
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Novartis Doubles Down on Palazestrant + Ribociclib Combo With Increased Phase 1/2 Study Size
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Trial Design Listed on Clinicaltrials.gov; Capital Raise Extends Cash Runway Into 2027
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Recap: Catalyst Rich 2H23 With Three Palazestrant Data Readouts Expected
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
OP-1250 + Palbo Data Validate Potential for the Combo to be Evaluated in 1L Patients; Increasing PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Recap: OP-1250 + Palbo ESMO Breast Abstract Points to an All-Around Positive Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Take: Restructuring Announcement Does Not Impact OP-1250 Development; Increasing PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Noteworthy Discussion Points From Our Meetings at
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
OP-1250 Safety Concerns in Combination With Palbo Can Be Put to Rest
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Take: Initial OP-1250 Combination Data With Palbociclib Expected 4Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1b Dose Expansion Establishes Broad Efficacy Potential of OP-1250; Safety Profile Appears Manageable
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Responses Validate OP-1250 Efficacy and Combination Tolerability Appears Not Concerning; 2Q22 Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
No Grade 3/4 Neutropenia Cases Seen in Dose Expansion; Upgrading to Buy With $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Take: All Timelines on Track With Data Updates Expected in 2022; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Olema Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Take: Focus Remains on Monotherapy and Combination Data in 2022; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department